PDF(Pubmed)
Abstract：
OBJECTIVE: To assess the value of intrauterine PRP to improve IVF outcome in women with previous implantation failure.
METHODS: Screening of Pubmed, Web of Science, and other databases from inception to August 2022 using the keywords related to \"platelet-rich plasma\" OR \"PRP\" AND \"IVF\" \"implantation failure.\" Twenty-nine studies (3308 participants) were included in our analysis, 13 were RCTs, 6 were prospective cohorts, 4 were prospective single arm, and 6 were retrospective analyses. Extracted data included settings of the study, study type, sample size, participants\' characteristics, route, volume, timing of PRP administration, and outcome parameters.
RESULTS: Implantation rate was reported in 6 RCTs (886 participants) and 4 non-RCTs (732 participants). The odds ratio (OR) effect estimate was 2.62 and 2.06, with 95% CI of 1.83, 3.76, and 1.03-4.11, respectively. Endometrial thickness was compared in 4 RCTs (307 participants) and 9 non-RCTs (675 participants), which showed a mean difference of 0.93 and 1.16, with 0.59-1.27 and 0.68-1.65 95% CI, respectively.
CONCLUSIONS: PRP administration improves implantation, clinical pregnancy, chemical pregnancy, ongoing pregnancy, live birth rates, and endometrial thickness in women with previous implantation failure.
METHODS: Screening of Pubmed, Web of Science, and other databases from inception to August 2022 using the keywords related to \"platelet-rich plasma\" OR \"PRP\" AND \"IVF\" \"implantation failure.\" Twenty-nine studies (3308 participants) were included in our analysis, 13 were RCTs, 6 were prospective cohorts, 4 were prospective single arm, and 6 were retrospective analyses. Extracted data included settings of the study, study type, sample size, participants\' characteristics, route, volume, timing of PRP administration, and outcome parameters.
RESULTS: Implantation rate was reported in 6 RCTs (886 participants) and 4 non-RCTs (732 participants). The odds ratio (OR) effect estimate was 2.62 and 2.06, with 95% CI of 1.83, 3.76, and 1.03-4.11, respectively. Endometrial thickness was compared in 4 RCTs (307 participants) and 9 non-RCTs (675 participants), which showed a mean difference of 0.93 and 1.16, with 0.59-1.27 and 0.68-1.65 95% CI, respectively.
CONCLUSIONS: PRP administration improves implantation, clinical pregnancy, chemical pregnancy, ongoing pregnancy, live birth rates, and endometrial thickness in women with previous implantation failure.
摘要：
目的：评估宫内PRP对改善先前植入失败的妇女IVF结局的价值。
方法：Pubmed，WebofScience,和其他数据库从开始到2022年8月使用与\"富血小板血浆\"或\"PRP\"和\"IVF\"植入失败相关的关键字。“29项研究(3308名参与者)被纳入我们的分析，13个是RCT，6个是前瞻性队列，4个是预期的单臂，6项为回顾性分析。提取的数据包括研究的设置，研究类型,样本量,参与者的特征，路线,volume,PRP管理的时间安排，和结果参数。
结果：在6个RCT（886名参与者）和4个非RCT（732名参与者）中报告了植入率。比值比（OR）效应估计为2.62和2.06，95%CI分别为1.83、3.76和1.03-4.11。比较了4个RCT（307名参与者）和9个非RCT（675名参与者）的子宫内膜厚度，其平均差为0.93和1.16，分别为0.59-1.27和0.68-1.6595%CI。
结论：PRP给药可改善着床，临床妊娠,化学妊娠,正在怀孕,活产率,和子宫内膜厚度在以前植入失败的妇女。
方法：Pubmed，WebofScience,和其他数据库从开始到2022年8月使用与\"富血小板血浆\"或\"PRP\"和\"IVF\"植入失败相关的关键字。“29项研究(3308名参与者)被纳入我们的分析，13个是RCT，6个是前瞻性队列，4个是预期的单臂，6项为回顾性分析。提取的数据包括研究的设置，研究类型,样本量,参与者的特征，路线,volume,PRP管理的时间安排，和结果参数。
结果：在6个RCT（886名参与者）和4个非RCT（732名参与者）中报告了植入率。比值比（OR）效应估计为2.62和2.06，95%CI分别为1.83、3.76和1.03-4.11。比较了4个RCT（307名参与者）和9个非RCT（675名参与者）的子宫内膜厚度，其平均差为0.93和1.16，分别为0.59-1.27和0.68-1.6595%CI。
结论：PRP给药可改善着床，临床妊娠,化学妊娠,正在怀孕,活产率,和子宫内膜厚度在以前植入失败的妇女。
